<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p67" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_67{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_67{left:341px;bottom:30px;}
#t3_67{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_67{left:377px;bottom:30px;}
#t5_67{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_67{left:540px;bottom:30px;}
#t7_67{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_67{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_67{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_67{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_67{left:285px;bottom:827px;letter-spacing:-0.32px;word-spacing:-0.15px;}
#tc_67{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_67{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_67{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_67{left:1123px;bottom:28px;letter-spacing:0.02px;}
#tg_67{left:36px;bottom:165px;}
#th_67{left:46px;bottom:159px;letter-spacing:0.12px;word-spacing:-0.03px;}
#ti_67{left:556px;bottom:159px;}
#tj_67{left:36px;bottom:148px;}
#tk_67{left:46px;bottom:142px;letter-spacing:0.1px;word-spacing:-0.04px;}
#tl_67{left:318px;bottom:142px;}
#tm_67{left:36px;bottom:131px;}
#tn_67{left:45px;bottom:125px;letter-spacing:0.1px;word-spacing:0.02px;}
#to_67{left:683px;bottom:125px;letter-spacing:0.13px;word-spacing:-0.04px;}
#tp_67{left:45px;bottom:108px;letter-spacing:0.03px;}
#tq_67{left:109px;bottom:108px;}
#tr_67{left:36px;bottom:778px;letter-spacing:0.46px;}
#ts_67{left:360px;bottom:778px;letter-spacing:0.36px;word-spacing:-0.32px;}
#tt_67{left:84px;bottom:649px;letter-spacing:-0.1px;}
#tu_67{left:84px;bottom:631px;letter-spacing:-0.1px;}
#tv_67{left:84px;bottom:612px;letter-spacing:-0.06px;}
#tw_67{left:84px;bottom:594px;letter-spacing:-0.09px;word-spacing:-0.1px;}
#tx_67{left:84px;bottom:576px;letter-spacing:-0.06px;}
#ty_67{left:84px;bottom:557px;letter-spacing:-0.1px;}
#tz_67{left:36px;bottom:438px;letter-spacing:-0.09px;}
#t10_67{left:36px;bottom:419px;letter-spacing:-0.1px;}
#t11_67{left:36px;bottom:401px;letter-spacing:-0.1px;}
#t12_67{left:84px;bottom:272px;letter-spacing:-0.09px;}
#t13_67{left:84px;bottom:254px;letter-spacing:-0.06px;}
#t14_67{left:84px;bottom:236px;letter-spacing:-0.1px;}
#t15_67{left:362px;bottom:720px;letter-spacing:-0.08px;}
#t16_67{left:275px;bottom:252px;letter-spacing:-0.35px;}
#t17_67{left:362px;bottom:645px;letter-spacing:-0.11px;}
#t18_67{left:362px;bottom:550.5px;letter-spacing:-0.11px;}
#t19_67{left:362px;bottom:455.3px;letter-spacing:-0.11px;}
#t1a_67{left:483px;bottom:672px;letter-spacing:-0.1px;}
#t1b_67{left:743px;bottom:680px;letter-spacing:-0.11px;}
#t1c_67{left:483px;bottom:654px;letter-spacing:-0.1px;}
#t1d_67{left:483px;bottom:636px;letter-spacing:-0.1px;}
#t1e_67{left:701px;bottom:643px;}
#t1f_67{left:713px;bottom:636px;letter-spacing:-0.09px;}
#t1g_67{left:483px;bottom:617px;letter-spacing:-0.13px;}
#t1h_67{left:506px;bottom:625px;}
#t1i_67{left:519px;bottom:617px;letter-spacing:-0.1px;}
#t1j_67{left:704px;bottom:625px;letter-spacing:-0.12px;}
#t1k_67{left:1079px;bottom:557px;letter-spacing:-0.09px;}
#t1l_67{left:1079px;bottom:539px;letter-spacing:-0.06px;}
#t1m_67{left:1079px;bottom:521px;letter-spacing:-0.08px;}
#t1n_67{left:1079px;bottom:502px;letter-spacing:-0.09px;}
#t1o_67{left:1079px;bottom:484px;letter-spacing:-0.25px;}
#t1p_67{left:483px;bottom:583px;letter-spacing:-0.1px;}
#t1q_67{left:743px;bottom:590px;letter-spacing:-0.09px;}
#t1r_67{left:483px;bottom:564px;letter-spacing:-0.09px;}
#t1s_67{left:568px;bottom:572px;}
#t1t_67{left:483px;bottom:546px;letter-spacing:-0.1px;}
#t1u_67{left:483px;bottom:528px;letter-spacing:-0.13px;}
#t1v_67{left:506px;bottom:535px;}
#t1w_67{left:483px;bottom:496px;letter-spacing:-0.09px;}
#t1x_67{left:583px;bottom:503px;}
#t1y_67{left:483px;bottom:477px;letter-spacing:-0.06px;}
#t1z_67{left:483px;bottom:459px;letter-spacing:-0.1px;}
#t20_67{left:726px;bottom:467px;}
#t21_67{left:483px;bottom:441px;letter-spacing:-0.1px;}
#t22_67{left:483px;bottom:422px;letter-spacing:-0.1px;}
#t23_67{left:867px;bottom:639px;letter-spacing:-0.09px;}
#t24_67{left:867px;bottom:618px;letter-spacing:-0.1px;}
#t25_67{left:867px;bottom:598px;letter-spacing:-0.09px;}
#t26_67{left:867px;bottom:578px;letter-spacing:-0.09px;}
#t27_67{left:36px;bottom:218px;}
#t28_67{left:46px;bottom:212px;letter-spacing:0.1px;word-spacing:0.02px;}
#t29_67{left:45px;bottom:196px;letter-spacing:0.11px;word-spacing:0.01px;}
#t2a_67{left:45px;bottom:179px;letter-spacing:0.13px;}
#t2b_67{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_67{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_67{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_67{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_67{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_67{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_67{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_67{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_67{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_67{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_67{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sa_67{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.sb_67{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sc_67{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sd_67{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
.t.m0_67{transform:matrix(0.999,0,0,1,0,0);}
</style>
<style id="fonts67" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

</style>
<div id="pg67Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg67" style="-webkit-user-select: none;"><object width="1210" height="935" data="67/67.svg" type="image/svg+xml" id="pdf67" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_67" class="t s0_67">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_67" class="t s1_67">® </span>
<span id="t3_67" class="t s0_67">(NCCN </span>
<span id="t4_67" class="t s1_67">® </span>
<span id="t5_67" class="t s0_67">), All rights reserved. NCCN Guidelines </span>
<span id="t6_67" class="t s1_67">® </span>
<span id="t7_67" class="t s0_67">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_67" class="t s2_67">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_67" class="t s2_67">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_67" class="t s3_67">NCCN Guidelines Version 4.2024 </span>
<span id="tb_67" class="t s3_67">Very Advanced Head and Neck Cancer </span>
<span id="tc_67" class="t s4_67">NCCN Guidelines Index </span>
<span id="td_67" class="t s4_67">Table of Contents </span>
<span id="te_67" class="t s4_67">Discussion </span>
<span id="tf_67" class="t s5_67">ADV-1 </span>
<span id="tg_67" class="t s6_67">a </span>
<span id="th_67" class="t s7_67">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="ti_67" class="t s8_67">. </span>
<span id="tj_67" class="t s6_67">b </span>
<span id="tk_67" class="t s7_67">Principles of Radiation Therapy (ADV-A)</span><span id="tl_67" class="t s8_67">. </span>
<span id="tm_67" class="t s6_67">c </span>
<span id="tn_67" class="t s8_67">When using concurrent systemic therapy/RT, the preferred agent is cisplatin (category 1). See </span><span id="to_67" class="t s7_67">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers </span>
<span id="tp_67" class="t s7_67">(SYST-A)</span><span id="tq_67" class="t s8_67">. </span>
<span id="tr_67" class="t s5_67">DIAGNOSIS </span><span id="ts_67" class="t s5_67">TREATMENT OF HEAD AND NECK CANCER </span>
<span id="tt_67" class="t s5_67">Newly diagnosed (M0) </span>
<span id="tu_67" class="t s5_67">T4b,N0–3 </span>
<span id="tv_67" class="t s5_67">or </span>
<span id="tw_67" class="t s5_67">Unresectable nodal disease </span>
<span id="tx_67" class="t s5_67">or </span>
<span id="ty_67" class="t s9_67" data-mappings='[[2,"fi"]]'>Unﬁt for surgery </span>
<span id="tz_67" class="t s5_67">Newly </span>
<span id="t10_67" class="t s5_67">diagnosed </span>
<span id="t11_67" class="t s5_67">disease </span>
<span id="t12_67" class="t s5_67">M1 disease at </span>
<span id="t13_67" class="t s5_67">initial </span>
<span id="t14_67" class="t s5_67">presentation </span>
<span id="t15_67" class="t s5_67">Clinical trial preferred </span>
<span id="t16_67" class="t sa_67">ADV-2 </span>
<span id="t17_67" class="t s5_67">PS 0–1 </span>
<span id="t18_67" class="t m0_67 s5_67">PS 2 </span>
<span id="t19_67" class="t m0_67 s5_67">PS 3 </span>
<span id="t1a_67" class="t s5_67">Concurrent systemic therapy/RT </span>
<span id="t1b_67" class="t sb_67">a,b,c </span>
<span id="t1c_67" class="t s5_67">or </span>
<span id="t1d_67" class="t s5_67">Induction systemic therapy </span>
<span id="t1e_67" class="t sb_67">a </span>
<span id="t1f_67" class="t s5_67">followed by </span>
<span id="t1g_67" class="t s5_67">RT </span>
<span id="t1h_67" class="t sb_67">b </span>
<span id="t1i_67" class="t s5_67">or systemic therapy/RT </span>
<span id="t1j_67" class="t sb_67">a,b </span>
<span id="t1k_67" class="t s5_67">Recurrent </span>
<span id="t1l_67" class="t s5_67">or </span>
<span id="t1m_67" class="t s5_67">persistent </span>
<span id="t1n_67" class="t s5_67">disease </span>
<span id="t1o_67" class="t sa_67">(ADV-3) </span>
<span id="t1p_67" class="t s5_67">Concurrent systemic therapy/RT </span>
<span id="t1q_67" class="t sb_67">a,b </span>
<span id="t1r_67" class="t s5_67">(preferred) </span>
<span id="t1s_67" class="t sb_67">1 </span>
<span id="t1t_67" class="t s5_67">or </span>
<span id="t1u_67" class="t s5_67">RT </span>
<span id="t1v_67" class="t sb_67">b </span>
<span id="t1w_67" class="t s5_67">Palliative RT </span>
<span id="t1x_67" class="t sb_67">b </span>
<span id="t1y_67" class="t s5_67">or </span>
<span id="t1z_67" class="t s5_67">Single-agent systemic therapy </span>
<span id="t20_67" class="t sb_67">a </span>
<span id="t21_67" class="t s5_67">or </span>
<span id="t22_67" class="t s5_67">Best supportive care </span>
<span id="t23_67" class="t sa_67">Post Systemic </span>
<span id="t24_67" class="t sa_67">Therapy/RT or RT </span>
<span id="t25_67" class="t sa_67">Neck Evaluation </span>
<span id="t26_67" class="t sa_67">(FOLL-A, 2 of 2) </span>
<span id="t27_67" class="t s6_67">1 </span>
<span id="t28_67" class="t sc_67">Patil VM, Noronha V, Menon N, et al. Results of phase III randomized trial for use of docetaxel </span>
<span id="t29_67" class="t sc_67">as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based </span>
<span id="t2a_67" class="t s8_67">chemoradiation. J Clin Oncol 2023;41:2350-2361. </span>
<span id="t2b_67" class="t sd_67">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
